UK Nurse’s Death Linked to Approved Weight-loss Drug

November 13, 2024
Memorial flowers

The death of a nurse from North Lanarkshire has been linked to the use of a weight-loss drug recently approved for use on the NHS.

Susan McGowan, 58, took two low-dose injections of tirzepatide, known under the brand name Mounjaro, over the course of about two weeks before her death on 4 September.

Her death certificate, seen by the BBC, lists multiple organ failure, septic shock and pancreatitis as the immediate cause of death – but “the use of prescribed tirzepatide” is also recorded as a contributing factor.

It is thought to be the first death officially linked to the drug in the UK.

Read more at BBC >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Massachusetts Med Spa Owner Pleads Guilty in Federal Counterfeit Injection Case
    • Merz Aesthetics’ Radiesse Receives FDA Approval for Décolleté Wrinkles
    • New Book “Get Found, Get Booked” Reveals a Smarter, Ethical Approach to Marketing for Med Spas and Wellness Practices
    • Bill Regulating Indiana Med Spas Has Passed: What You Need to Know and Why Collective Advocacy Matters
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics